What Is Carteolol Hydrochloride Eye Drops Used For?

Carteolol hydrochloride ophthalmic solution is a non-selective beta-adrenergic blocking agent used primarily in the management of elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. By inhibiting beta-1 and beta-2 adrenergic receptors in the ciliary epithelium, it reduces aqueous humor production—thereby lowering IOP without significantly affecting outflow facility. Unlike some other beta-blockers, carteolol possesses intrinsic sympathomimetic activity (ISA), which may contribute to a more favorable cardiovascular safety profile in certain patients, though clinical significance remains debated.

The medication is typically administered one drop into the affected eye(s) twice daily. Its onset of action occurs within 30 to 60 minutes, with peak IOP-lowering effects observed at approximately two hours post-instillation and sustained efficacy over 12 hours. Carteolol is metabolized hepatically via glucuronidation and excreted predominantly through the kidneys; dose adjustments are recommended in patients with moderate-to-severe renal impairment.

Common ocular adverse effects include transient stinging or burning upon instillation, blurred vision, conjunctival hyperemia, and dry eyes. Systemic side effects—though less frequent due to topical administration—may include bradycardia, bronchospasm (particularly in patients with asthma or chronic obstructive pulmonary disease), fatigue, and cold extremities. Contraindications include sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, and active bronchial asthma.

Clinical guidelines position carteolol as a second-line option when first-line agents such as prostaglandin analogs or topical carbonic anhydrase inhibitors are contraindicated or insufficiently effective. Its utility lies in its predictable IOP reduction—typically 20–30% from baseline—and relatively low incidence of corneal anesthesia or systemic hypotension compared with timolol. Ongoing monitoring of both IOP and systemic vital signs is advised during long-term therapy.